|
|
Profile
|
Delegates :
Hiroyuki Mabuchi |
|
Incorporated :
January 23 , 2018 |
Paid in Capital :
537 Million yen |
Employees :
12 人 |
Address :
Shiba-Daimon 1-2-14 H10 Hamamatsucho 613, Minato-ku TOKYO
〒105-0012
|
TEL/FAX :
+81-3-6670-2537 / |
URL：
https://www.aiwelljapan.com/en/ |
Attachment :
|
Mission/Background :
aiwell Inc. is a biotechnology company spun out from Tokyo Institute of Science, specializing in next-generation proteomics innovation. Our core platform, AI Proteomics (R), integrates two-dimensional electrophoresis-based protein imaging with proprietary AI-driven pattern recognition to detect early molecular signatures of disease, pre-symptomatic conditions, and biological state transitions with high precision.
aiwell operates multiple R&D hubs, including the Campus Innovation Center (INDEST), Tamachi Innovation Center, and the Proteomics Innovation Center (PIC) in Shin-Kawasaki. This distributed infrastructure enables rapid industry-academic co-development, accelerating translation from research to real-world application. Our mission is to eliminate pre-symptomatic disease globally through predictive biology, and to deliver high-value solutions that empower early intervention, personalized health management, and scientific innovation across medicine, agriculture, and health-related industries. |
|
Technology & Business
|
aiwell's AI Proteomics (R) technology dramatically reduces the cost and time traditionally required for proteome-wide analysis. By digitally capturing full protein-spot patterns and applying advanced AI comparison algorithms, the platform detects subtle expression shifts that indicate emerging biological change. This approach is applicable across humans, livestock, plants, and food materials-positioning AI Proteomics (R) as a cross-species biological analytics technology with wide industrial utility.
In 2025, we launched aiwell IPA (Integrated Proteomics Analysis), combining AI-based 2-DE image analytics with LC-MS/MS mass spectrometry to deliver seamless, high-resolution protein identification and network-level mechanistic insight. This integrated workflow enables rapid biomarker discovery, causal-factor inference using proprietary algorithms, and comprehensive profiling that supports drug discovery, toxicology, evaluation, precision diagnostics, and scientific validation in diverse res
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
aiwell care
|
Launched
|
Home-use micro-sample blood test kit enabling up to 45 clinical-grade biomarkers.
|
Scaling adoption across corporate health programs and consumer wellness.
|
aiwell care Nutrition+
|
Launched
|
Nutrition analysis service integrating blood data with dietary assessment by registered dietitians.
|
Expand data-driven personalized nutrition programs.
|
aiwell IPA (Integrated Proteomics Analysis)
|
Service/Marketing
|
Hybrid workflow combining AI-based 2-DE analysis with LC MS/MS for high precision proteomic profiling.
|
Strengthen adoption in pharmaceutical R&D and translational biology
|
|
|
|
|
|
|
|
|
|
Highlights
|
In 2025, aiwell launched aiwell IPA, integrating AI-based proteome comparison with LC-MS/MS to provide high-precision, cost-effective analysis. The Proteomics Innovation Center (PIC), established in 2023 and expanded in 2025, now supports end-to-end biomarker discovery, drug-research collaboration, and multi-species analytics with enhanced capacity for external research partnerships.
|
|
Hot news
|
aiwell continues strengthening its intellectual property portfolio, acquiring and filing multiple patents between 2025-2026, including:
- Non wash protein gel staining reagent (JP Patent No. 7113446)
- Information processing system (JP Patent No. 7215682)
- Information processing system and program (JP 2024 000582, under review)
|
|
Alliance strategy
|
aiwell seeks strategic collaboration in multiple domains:
- Joint R&D with pharmaceutical and drug discovery companies using AI Proteomics (R)
- Partnerships with hospitals and clinics for early diagnosis and pre symptomatic health programs
- Cooperation with corporations and municipalities advancing health management initiatives
- Alliances with livestock, agricultural, and food industry players to apply proteomics across biological sectors
|
|
|